Accurate monitoring of the disease by repeated serum tumour marker determinations is an important element of the successful management of malignant germ cell tumours. In non-seminoma the serum levels of choriogonadotropin (HCG) and/or of alfa-foeto-protein (AFP) are elevated in about 70% of the patients with tumour manifestations (Fossa et al., 1989) . HCG is the most specific tumour marker in seminoma, but with a low sensitivity (Fossa & Fossa, 1989) . There is a need for other tumour markers which may be helpful to monitor the clinical course in patients with seminoma.
Neuron-specific enolase (NSE) is recognised as a valuable tumour marker in small cell lung cancer (Carney et al., 1982) , melanoma (Wibe et al., 1990) and other neuroendocrine malignancies (Heitz, 1987) . NSE has been demonstrated in cells from testicular germ cell tumours, in particular in seminomas (Kuzmits et al., 1987; Niehans et al., 1988) . Based on small series, Kusznitz et al. (1987) and Takashi et al. (1990) suggested that NSE may represent a valuable tumour marker in seminoma (Kuzmits et al., 1987 , Takashi et al., 1990 .
The aim of the present retrospective pilot study was furthermore to assess the hypothesis that the determination of serum NSE might be worthwhile in the management of patients with seminoma. (Fossa & Fossa, 1989) . The upper limits of the normal ranges were 10 U 1 for HCG and 450 U 1-' for LDH.
Patients and methods

Patients
NSE was measured by an immunoradiometric assay based on monoclonal antibodies employing monodisperse magnetisable particles as the solid phase (Paus & Nustad, 1989 ). This method is specific for y-enolase, measures wy-and yyenolase equally well, has a sensitivity of 0.4 tg I1-and an interassay coefficient of variation below 5% in the working range from 0.4 to 170 lgl-'. The 97.5th percentile value of the reference population was found at 8 jig I-I (Paus & Nustad, 1989) . NSE values exceeding 8 tgl-1 were considered elevated. All results are given without decimals.
Results
NSE was < 8 yg l'-in all patients from the control group (Table Ia) .
Before orchiectomy, three of the 21 patients with stage I seminoma had elevated serum NSE, but normal HCG, and in three additional patients both markers were increased (Table Ia) . In all four evaluable patients with elevated preorchiectomy serum NSE, this marker normalised after orchiectomy (Figure la) .
Eleven of 16 patients with metastases had elevated NSE before orchiectomy, four of them combined with elevated HCG. Figure lb shows Figure   2b ). After treatment he still had a small residual para-aortic mass (partial response), a frequent finding after chemotherapy of advanced seminoma.
Discussion
The need of new tests to monitor the clinical course of seminoma is well recognised. HCG is elevated in about 30-50% of the patients with manifest seminoma, dependent on the assay used (Paus et al., 1988) . LDH is elevated in 80% of the patients with active tumour (Fossa & Fossa, 1989) Figure 2a shows the development of serum NSE in a patient presenting with seminoma stage I who developed skeletal metastases 8 months after infradiaphragmatic radiotherapy and responded completely to subsequent chemotherapy/radiotherapy. The first serum NSE level (10igl1') was available 2 months after infradiaphragmatic radiotherapy. Four months later he presented with bone metastases. Serum NSE was at that time measured on two occasions (22 jig 1-and 43 jg 1 '). After subsequent chemotherapy and radiotherapy serum NSE normalised. In this patient, HCG remained normal during the course of the disease, while LDH was elevated before start of chemotherapy and normalised subsequently. In another patient with an extragonadal stage IIIC seminoma with raised pre-treatment values of NSE and HCG the nrarkers normalised after cisplatin-based chemo- ,.)A nine raised HCG. NSE was the only elevated marker in two out of 14 patients with tumour, in whom both NSE, LDH and HCG were determined. No patient with falsely elevated NSE was observed.
Changes of NSE efficiently monitored treatment response: In stage I seminoma orchiectomy led to normalisation of NSE in all patients who had elevated values before the operation. During chemotherapy any raised NSE levels normalised in all patients. NSE might be elevated due to other malignancies (Carney et al., 1982; Wibe et al., 1990; Heitz, 1987) . The possibility of a new primary tumour should therefore be kept in mind if a patient with a prior history of seminoma presents with high NSE levels, especially if the elevated NSE is found many years after the initial treatment of seminoma. In particular, NSE represents a tumour marker both for lung cancer and malignant melanoma. Both malignancies seem to occur at an increased risk in patients cured for testicular cancer (FossA et al., 1990 
